RecruitingPhase 1NCT06756932
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Studying Epidermal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeOne Medicines
- Principal Investigator
- Study DirectorBeOne Medicines
- Intervention
- BGB-21447(drug)
- Enrollment
- 120 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (16)
- Hoag Memorial Presbyterian, Newport Beach, California, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Md Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
- Saint Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
- Calvary Mater Newcastle, Waratah, New South Wales, Australia
- Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia
- Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
- Western Health Sunshine Hospital, St Albans, Victoria, Australia
- Linear Clinical Research, Nedlands, Western Australia, Australia
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
- Fudan University Shanghai Cancer Centerpudong, Shanghai, Shanghai Municipality, China
- Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06756932 on ClinicalTrials.govOther trials for Epidermal disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07222215PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Kristina A. Fanucci
- RECRUITINGPHASE1NCT07214662A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerGenentech, Inc.
- RECRUITINGPHASE1, PHASE2NCT07049055A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic CancerEngeneic Pty Limited
- RECRUITINGPHASE1NCT07361237A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationsTongji University
- RECRUITINGPHASE2, PHASE3NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07216183Epidermal Sensors for Wireless and Enhanced Amputee Skin Tracking (E-SWEAT) Part 1North Carolina State University
- RECRUITINGPHASE3NCT06982521Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRelay Therapeutics, Inc.
- RECRUITINGPHASE2NCT06348134Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryUniversity of Chicago